Drug major Cipla has acquired the nutrition products portfolio from Mumbai-based Wanbury for an undisclosed sum.
The acquisition, aimed at strengthening Cipla’s women’s health segment, comprises four brands — CPink, CDense, Productiv, and Folinine. CPink is used to treat anaemia, CDense is used for calcium deficiency, Productiv is used to treat infertility, and Folinine is a folic acid tablet. According to IQVIA (December Moving Annual Turnover), the four molecules have a market size of Rs 3,100 crore in India. At present, these brands clock a sales value of Rs 59.6 crore for Wanbury.
Cipla said the nutraceutical products, to be sold under